LSL Pharma Group Inc.LSL.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · groupelslpharma.com
LSL Pharma Group develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products for the Canadian, U.S., and international markets through subsidiaries including Steri-Med Pharma, Laboratoire LSL, Virage Santé, and Dermolab Pharma.
Key ratios
FCF / Sales
1.6%TTM
2024
-18.3%2023
-77.0%2022
-50.7%
Net margin
10.4%TTM
2024
18.7%2023
-84.5%2022
-98.2%
ROA
1.8%TTM
2024
0.6%2023
-8.8%2022
-15.0%
ROE
12.1%TTM
2024
19.8%2023
-121.5%2022
-98.3%
Revenue growth
69.4%TTM
2024
77.0%2023
22.1%2022
-6.4%
Recent news
LSL Pharma Group Announces CFO Transition
LSL Pharma Group Reports Record Revenues and Second Quarter 2026 Results
LSL Pharma Group Provides Update on Steri-Med Pharma Manufacturing Operations and Grants Compensation Stock Options
LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
Track LSL.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer